Onco Actu du 21 avril 2020

	1. BIOLOGIE
Finding leukemia's weakness using genome-wide CRISPR technology [UC San Diego] Reporting in the April 20, 2020 online edition of the journal Nature Cancer, Reya and colleagues identified RNA-binding proteins — which normally control how, when and if cells make certain proteins — as a key class of proteins that sustain and protect drug-resistant leukemia stem cells.
	3.4.1 CHIMIOPRÉVENTION - ASPIRINE
Daily Aspirin Tied to Lower Risk of Various Digestive Cancers [NY Times] Researchers pooled data from 113 studies and found that daily aspirin use among people aged 40 to 75 was associated with a 27 percent reduction in the risk for colorectal cancer, a 36 percent reduction in stomach cancer, a 33 percent reduction in esophageal cancer, a 38 percent reduction in liver and gallbladder cancer, and a 22 percent reduction in pancreatic cancer.
	4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer [Roche] cobas 6800/8800 Systems deliver full automation, helping laboratories meet the throughput and efficiencies that high-volume, HPV DNA screening programs require.
	5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
Positive data keep Bristol Myers and Exelixis in the kidney cancer race [Biopharma Dive] The data appear to roughly match the Keytruda-Inlyta results on both delaying death and disease progression, although there is no head-to-head comparison.
Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma [BMS] Study met primary endpoint of significantly improving progression-free survival, and secondary endpoints of overall survival and objective response rate vs. sunitinib.
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion [EndPoints] In combination with the pharma giant’s checkpoint inhibitor Opdivo, Exelixis’ once-daily pill Cabometyx improved progression-free survival and overall survival in patients with renal cell carcinoma, a form of kidney cancer.
	5.12.4 IMMUNOTHÉRAPIES - ESSAIS
Bristol Myers Squibb's Opdivo-Yervoy combo helps mesothelioma patients live longer [Fierce Pharma] An indication in MPM would add another notch to the pairing’s belt. The regimen already bears go-aheads in melanoma, kidney cancer and liver cancer, among others.
Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma [BMS] "We look forward to working with investigators to present the results at a future medical meeting, and to discussing them with health authorities.”
	5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - PEMIGATINIB
Incyte beefs up portfolio with FDA nod for rare bile duct cancer therapy Pemazyre [Fierce Pharma] Pemazyre will hit the market at a list price of $17,000 per treatment cycle, a price point that is "appropriate given the potential benefit it brings to this underserved population," Barry P. Flannelly, Incyte's executive VP and U.S. general manager, said on a Monday morning call with analysts.
FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer [Xconomy] The FDA based its approval of pemigatinib on an open-label study that enrolled 107 patients. Patients received the Incyte pill once a day for 14 days, followed by seven days off. That treatment cycle continued until the disease progressed or side effects led patients to stop.
	6.1 OBSERVATION
Breastfeeding May Lower Risk of Ovarian Cancer [NY Times] Nursing for three months was associated with an 18 percent lower risk of ovarian cancer, and for more than a year with a 34 percent lower risk. The pooled analysis, in JAMA Oncology, included 13 studies with 9,973 ovarian cancer cases and 14,843 controls.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
How coronavirus is impacting cancer services in the UK [Cancer Research UK] And while health bodies and governments have noble ambitions for cancer treatment and care, change won’t materialise without adequate resource and a coordinated response combined with mass COVID-19 testing.
Cancer and COVID-19; how do we manage cancer optimally through a public health crisis? [European Journal of Cancer] The COVID-19 pandemic needs to be managed, but not at the expense of significant lost lives and suffering in cancer patients. Cancer, like coronavirus does not respect national borders. Neither should we.
COVID-19: impact on cancer workforce and delivery of care [Lancet Oncology] Cancer specialists predict that new ways of working in cancer care during the COVID-19 pandemic will permanently change oncology services, after evaluating their impact. Slotman said, “This pandemic has led to new ways of working together and we should try to keep the best changes after the pandemic is over.”